Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z
Cells. 2025; 14(5).
PMID: 40072110
PMC: 11898822.
DOI: 10.3390/cells14050382.
Amissah H, Antwi M, Amissah T, Combs S, Shevtsov M
Cells. 2025; 14(3).
PMID: 39936995
PMC: 11817126.
DOI: 10.3390/cells14030204.
Zuo Q, Kang Y
Adv Exp Med Biol. 2025; 1464():347-370.
PMID: 39821033
DOI: 10.1007/978-3-031-70875-6_17.
Das F, Ghosh-Choudhury N, Kasinath B, Sharma K, Ghosh Choudhury G
PLoS One. 2025; 20(1):e0311828.
PMID: 39761275
PMC: 11703087.
DOI: 10.1371/journal.pone.0311828.
Senyigit A, Durmus S, Oruc A, Gelisgen R, Uzun H, Tabak O
Medicina (Kaunas). 2024; 60(11).
PMID: 39596932
PMC: 11595949.
DOI: 10.3390/medicina60111744.
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.
Gharib E, Robichaud G
Int J Mol Sci. 2024; 25(17).
PMID: 39273409
PMC: 11395697.
DOI: 10.3390/ijms25179463.
Synergy between isobavachalcone and doxorubicin suppressed the progression of anaplastic thyroid cancer through ferroptosis activation.
Lin S, Cai H, Song X
Braz J Med Biol Res. 2024; 57:e13679.
PMID: 39166605
PMC: 11338552.
DOI: 10.1590/1414-431X2024e13679.
LncRNA NONHSAT227443.1 Confers Esophageal Squamous Cell Carcinoma Chemotherapy Resistance by Activating PI3K/AKT Signaling via Targeting MRTFB.
Wang Y, Wang Y, Zhang J, Shi Z, Liu J
Technol Cancer Res Treat. 2024; 23:15330338241274369.
PMID: 39150441
PMC: 11329966.
DOI: 10.1177/15330338241274369.
A systematic review of mechanisms of PTEN gene down-regulation mediated by miRNA in prostate cancer.
Bergez-Hernandez F, Irigoyen-Arredondo M, Martinez-Camberos A
Heliyon. 2024; 10(15):e34950.
PMID: 39144981
PMC: 11320309.
DOI: 10.1016/j.heliyon.2024.e34950.
Efficacy and Mechanism of Core Traditional Chinese Medicines for Treating Malignant Lymphoma based on Efficacy Studies: A Study Supported by Network Pharmacology and Molecular Docking.
Jin J, Ren S, Han B, Zhang W, Xu H, Yang J
Curr Pharm Des. 2024; 30(33):2652-2666.
PMID: 39082169
DOI: 10.2174/0113816128308565240710114350.
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
Park W, Wei S, Xie C, Han J, Kim B, Kim B
Exp Mol Med. 2024; 56(5):1137-1149.
PMID: 38689087
PMC: 11148081.
DOI: 10.1038/s12276-024-01221-2.
Inhibition of Carbohydrate Metabolism Potentiated by the Therapeutic Effects of Oxidative Phosphorylation Inhibitors in Colon Cancer Cells.
Guo L, Zhang B, Zhang W, Xie Y, Chen X, Sun X
Cancers (Basel). 2024; 16(7).
PMID: 38611076
PMC: 11010912.
DOI: 10.3390/cancers16071399.
Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway.
Heisnam R, Devi S, Mohanty S, Mukherjee P, Rayala V, Radhakrishnanand P
Am J Cancer Res. 2024; 14(3):1071-1086.
PMID: 38590426
PMC: 10998759.
DOI: 10.62347/JTNQ4812.
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam P, Are C
Int J Mol Sci. 2024; 25(6).
PMID: 38542151
PMC: 10970097.
DOI: 10.3390/ijms25063178.
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.
Raskova Kafkova L, Mierzwicka J, Chakraborty P, Jakubec P, Fischer O, Skarda J
Front Immunol. 2024; 15:1342086.
PMID: 38384472
PMC: 10879685.
DOI: 10.3389/fimmu.2024.1342086.
Phosphoinositide switches in cell physiology - From molecular mechanisms to disease.
Lolicato F, Nickel W, Haucke V, Ebner M
J Biol Chem. 2024; 300(3):105757.
PMID: 38364889
PMC: 10944118.
DOI: 10.1016/j.jbc.2024.105757.
Synthesis and Biological Evaluation of β-Lactam Derivatives Targeting Speckle-Type POZ Protein (SPOP).
Zhou C, Hao X, Chen Z, Zhang R, Zhou Q, Fan Z
ACS Med Chem Lett. 2024; 15(2):270-279.
PMID: 38352842
PMC: 10860195.
DOI: 10.1021/acsmedchemlett.3c00515.
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.
Albadari N, Xie Y, Li W
Front Pharmacol. 2024; 14:1340401.
PMID: 38269272
PMC: 10806212.
DOI: 10.3389/fphar.2023.1340401.
Oxidized Low-Density Lipoprotein Accumulation in Macrophages Impairs Lipopolysaccharide-Induced Activation of AKT2, ATP Citrate Lyase, Acetyl-Coenzyme A Production, and Inflammatory Gene H3K27 Acetylation.
Ting K, Yu P, Iyayi M, Dow R, Hyduk S, Floro E
Immunohorizons. 2024; 8(1):57-73.
PMID: 38193847
PMC: 10835650.
DOI: 10.4049/immunohorizons.2300101.
Depletion of slow-cycling PDGFRαADAM12 mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis.
Di Carlo S, Raffenne J, Varet H, Ode A, Cabrerizo Granados D, Stein M
Nat Immunol. 2023; 24(11):1867-1878.
PMID: 37798557
PMC: 10602852.
DOI: 10.1038/s41590-023-01642-7.